全视网膜光凝联合雷珠单抗治疗重度非增殖性糖尿病性视网膜病变的临床效果

Abstract
Figure/Table
References (16)
Related Citation (4)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of panretinal photocoagulation combined with Ranibizumab treating severe non-proliferative diabetic retinopathy (DR). Methods A total of 96 patients with severe non-proliferative DR admitted to Shangrao Aier Eye Hospital from August 2019 to August 2020 were selected as the research objects and divided to the control group (48 cases) and the study group (48 cases) according to the random ballot method. The control group was treated with panretinal photocoagulation, and the study group was treated with panretinal photocoagulation combined with Ranibizumab. The clinical efficacy, best corrected visual acuity (BCVA), intraocular pressure (IOP),central macular thickness (CMT) and adverse reactions were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group, the difference was statistically significant (P<0.05).There was no significant difference in BCVA between the two groups before treatment (P>0.05). After treatment, the BCVA of the study group lower than that of the control group, the difference was statistically significant (P<0.05). There were no significant differences in IOP and CMT between the two groups before treatment (P>0.05). After treatment, the IOP and CMT of the study group were lower than those of the control group, the differences were statistically significant(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Panretinal photocoagulation combined with Ranibizumab could effectively improve the vision of patients with severe non-proliferative DR, reduce IOP and CMT. It has certain clinical effect.

Key words： Ranibizumab Panretinal photocoagulation Severe non-proliferative diabetic retinopathy Correct vision

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Ding-yong

Cite this article:

WU Ding-yong. Clinical effect of panretinal photocoagulation combined with Ranibizumab treating severe non-proliferative diabetic retinopathy[J]. 中国当代医药, 2021, 28(16): 50-52转56.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I16/50

[1]	蒋利生.玻璃体腔注射雷珠单抗联合全视网膜光凝及单纯全视网膜光凝治疗高危增殖性糖尿病视网膜病变疗效探讨[J].中国保健营养，2020，30（23）：325.
[2]	钟志伟，邵东平.玻璃体腔注射雷珠单抗联合全视网膜光凝及单纯全视网膜光凝治疗高危增殖性糖尿病视网膜病变的对比研究[J].海南医学，2019，30（11）：1401-1403.
[3]	万小波.眼底激光单用和联合雷珠单抗治疗糖尿病性视网膜病变患者的疗效及对完全吸收时间的影响[J].中国医学创新，2019，16（27）：62-65.
[4]	杨乐，薛雨顺，石蕊.玻璃体腔注射雷珠单抗联合超全视网膜光凝治疗视盘新生血管型糖尿病视网膜病变[J].国际眼科杂志，2018，18（9）：1710-1712.
[5]	李奎阳.雷珠单抗联合激光治疗增殖性糖尿病视网膜病变[J].河南医学研究，2020，29（32）：6008-6010.
[6]	刘青，艾明.雷珠单抗联合全视网膜光凝辅助玻璃体切割手术治疗糖尿病视网膜病变[J].国际眼科杂志，2016，16（9）：1637-1640.
[7]	康凯，王闰，郑继伟，等.雷珠单抗和视网膜激光对糖尿病性视网膜病变黄斑囊样水肿治疗临床分析[J].黑龙江医药科学，2019，42（2）：118-119.
[8]	沈朝兰，崔凌，黄慧，等.微创玻璃体切割术前不同间隔时间玻璃体腔内注射雷珠单抗辅助治疗增殖性糖尿病视网膜病变的疗效及安全性[J].广西医学，2018，40（24）：2876-2879.
[9]	徐建龙，马青.改良全视网膜激光光凝术治疗糖尿病性视网膜病变的临床效果及对血清VEGF 水平的影响[J].影像科学与光化学，2020，38（2）：301-306.
[10]	张洪杰.玻璃体腔内注射雷珠单抗联合视网膜光凝治疗增殖期糖尿病视网膜病变的效果[J].中国保健营养，2017，27（17）：85.
[11]	陈辑.全视网膜激光光凝术联合玻璃体腔内注射康柏西普对增生性糖尿病视网膜病变患者视功能恢复的影响[J].影像科学与光化学，2020，38（1）：87-93.
[12]	段勇波，赵奋图，沈泳芝.康柏西普联合全视网膜光凝治疗进展型糖尿病性视网膜病变患者的临床效果[J].医疗装备，2020，33（17）：115-117.
[13]	吕涛，侯传俊.视网膜光凝治疗糖尿病性视网膜病变的临床疗效[J].中国医药指南，2020，18（32）：105-106.
[14]	Bressler SB，Beaulieu WT，Glassman AR，et al.Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy：Factors Associated with Vision and Edema Outcomes[J].Ophthalmology，2018，125（11）：1776-1783.
[15]	刘矫连，左慧懿，衷昕.康柏西普玻璃体腔注射联合全视网膜光凝术治疗合并黄斑水肿的重度非增殖性糖尿病视网膜病变[J].山东医药，2020，60（30）：89-91.
[16]	李婷婷.全视网膜激光光凝治疗对糖尿病性视网膜病变患者眼内炎性因子的影响[J].中国医药指南，2020，18（33）：26-28.